Dermata Therapeutics Inc
NASDAQ:DRMA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.86
14.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Dermata Therapeutics Inc
Net Income (Common)
Dermata Therapeutics Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Dermata Therapeutics Inc
NASDAQ:DRMA
|
Net Income (Common)
-$12.3m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income (Common)
$25.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income (Common)
$6B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
13%
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Income (Common)
$9.8B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income (Common)
$19B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income (Common)
$18.4B
|
CAGR 3-Years
45%
|
CAGR 5-Years
27%
|
CAGR 10-Years
23%
|
|
Dermata Therapeutics Inc
Glance View
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2021-08-13. The firm focuses on the treatment of medical and aesthetic skin conditions. Its lead product candidate, DMT310, is a product candidate, which is developed from its Spongilla technology platform. DMT310 is a topical product derived from sourced freshwater sponge with multiple components. Its DMT310 is under clinical development for the treatment of acne vulgaris (acne), psoriasis vulgaris (psoriasis), and papulopustular rosacea (rosacea). The Company’s Spongilla technology platform is based on the use of a naturally growing freshwater sponge, Spongilla lacustris (Spongilla). Spongilla is a freshwater sponge that grows in rivers and lakes in commercial quantities in select regions of the world, such as the northern hemisphere. Its clinical development pipeline consists of DMT310 and DMT410.
See Also
What is Dermata Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-12.3m
USD
Based on the financial report for Dec 31, 2024, Dermata Therapeutics Inc's Net Income (Common) amounts to -12.3m USD.
What is Dermata Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-21%
Over the last year, the Net Income (Common) growth was -58%. The average annual Net Income (Common) growth rates for Dermata Therapeutics Inc have been -5% over the past three years , -21% over the past five years .